Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.4%, 39.1% on TOFA 5 BID, TOFA 10 BID, adalimumab, & placebo. Effective RA Rx w/ Tofa or ADA lead to improved depression and anxiety https://t.co/y6UoFXANo7 https://t.co/aV5uV9qWbz